Safety and Efficacy of Hydrogen Peroxide Topical Solution, 40% (w/w), in Patients with Seborrheic Keratosis: A Follow up Study
Keywords:
HP40, Hydrogen peroxide, Seborrheic keratosisAbstract
Introduction: Seborrheic keratosis are common benign epidermal tumors developing after middle-age. Approved topical treatments for seborrheic keratosis (SKs) are an unmet need. Objective: To evaluate the safety and efficacy of 40% hydrogen peroxide topical solution (HP40) versus vehicle for the treat ment of SKs. Methodology: A total of 50 patients with at least 2 SKs were selected and one lesion on each patient was treated with HP40 and the other with vehicle. Follow up was done at 3, 7 and 15 weeks. At each visit, SKs were graded using the Physician’s Le sion Assessment (PLA) scale (0=clear; 1= nearly clear; 2=<1 mm thick; and 3=>1 mm thick). Solution was applied at first visit and at 3 weeks if PLA score was higher than 0. Results: At 15 weeks, significantly more patients treated with HP40 than with vehicle achieved a PLA score of 0 (42% versus 0). Mean PLA score at 15 weeks was 0.82±0.87 in HP40 group and 2.96±0.2 in control group (p<0.001). Local skin reaction was only mild burning sensation and resolved within few days. Conclusion: Application of HP40 was well tolerated and effective in the removal of SKs.
References
Bickers, DR., Lim, HW., Margolis, D., Weinstock, MA., Goodman, C., Faulkner, E., et al. (2006) The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. J Am Acad Dermatol, 55(3): 490-500.
Del Rosso, JQ. (2017) A closer look at seborrheickeratoses: patient perspectives, clinical relevance, medical necessity, and implications for management. J Clin Aesthet Dermatol, 10(3): 16-25.
DuBois, JC., Jarratt, M., Beger, BB., Bradshaw, M., Powala, CV., Shanler, SD. (2018) A-101, a proprietary topical formulation of high-concentration hydrogen peroxide solution: a randomized, double-blind, PBO-controlled, parallel group study of the dose-response profile in patients with seborrheic keratosis of the face. Dermatol Surg, 44(3): 330-340.
Jackson, JM., Alexis, A., Berman, B., Berson, DS., Taylor, S., Weiss, JS. (2015) Current understanding of seborrheic keratosis: prevalence, etiology, clinical presentation, diagnosis, and management. J Drugs Dermatol, 14(10): 1119- 1125.
Ranasinghe, GC., Friedman, AJ. (2017) Managing seborrheickeratoses: evolving strategies for optimizing patient outcomes. J Drugs Dermatol, 16(11): 1064-1068.
Levy-Nissenbaum, E., Thio, HB., Burstein, P., Thaci, D. (2015) Seborrhoeic keratosis removal in a multicentre phase I/II clinical trial using a novel topical formulation (BL-5010). Br J Dermatol, 173(1): 247-249.
Kim, KW., Chang, J., Lee, S., Jung Im, G., Won Chae, S., Hyun Jung, H., et al. (2015) Clinical analysis of seborrheickeratoses in the ear: a retrospective study and literature review. Eur Arch Otorhinolaryngol, 272(5): 1113-1117.
Hiraishi, Y., Hirobe, S., Iioka, H., Ying-Shu, Q., Kamiyama, F., Asada, H., et al. (2013) Development of a novel therapeutic approach using a retinoic acid-loaded microneedle patch for seborrheic keratosis treatment and safety study in humans. J Control Release, 171(2): 93-103.
Burge, SM., Bristol, M., Millard, PR., Dawber, RPR. (1986) Pigment changes in human skin after cryotherapy. Cryobiology, 23(5): 422-432.
(1991) Guidelines of care for cryosurgery. American Academy of Dermatology Committee on Guidelines of Care. J Am Acad Dermatol, 31(4): 648-653.
US Centers for Disease Control and Prevention. National Institute for Occupational Safety and Health (NIOSH). Hydrogen peroxide.
Mastrangelo, G., Zanibellato, R., Fadda, E., Lange, JH., Scoizzato, L., Rylander, R. (2009) Exposure to hydrogen peroxide and eye and nose symptoms among workers in a beverage processing plant. Ann Occup Hyg, 53(2): 161- 165.
Kaelin, RM., Kapanci, Y., Tschopp, JM. (1988) Diffuse interstitial lung disease associated with hydrogen peroxide inhalation in a dairy worker. Am Rev Respir Dis, 137(5): 1233-1235.
Suenaka, T., Akaska, S., Hirata, M. (1984) A survey of occupational exposure to hydrogen peroxide H O exposure 2 2 level and its effects on lipid peroxide and its related enzyme activities. Proceedings of Osaka Prefecture Institute of Public Health, Edition of Industrial Health, 22: 9-13.
Yoon, JJ., Jeong, JW., Choi, EO., Kim, MJ., Bo, HH., Kim, HJ., et al. (2017) Protective effects of Scutellariabaicalensis- Georgi against hydrogen peroxide-induced DNA damage and apoptosis in HaCaT human skin keratinocytes. EXCLI J, 16: 426-438.
Yang, B., Yang, Q., Yang, X., et al. (2016) Hyperoside protects human primary melanocytes against H O -induced 2 2 oxidative damage. Mol Med Rep, 13(6): 4613-4619.
Bekeschus, S., Kolata, J., Winterbourn, C., Kramer, A., Turner, R., Weltmann, KD., et al. (2014) Hydrogen peroxide: a central player in physical plasma-induced oxidative stress in human blood cells. Free Radic Res, 48(5): 542-549.
Oyewole, AO., Wilmot, MC., Fowler, M., Birch-Machin, MA. (2014) Comparing the effects of mitochondrial targeted and localized antioxidants with cellular antioxidants in human skin cells exposed to UVA and hydrogen peroxide. FASEB J, 28(1): 485-494.
Kao, S., Kiss, A., Efimova, T., Friedman, A. (2018) An ex-vivo evaluation of cytotoxicity and melanocyte viability after A-101 hydrogen peroxide topical solution 40% or cryosurgery treatment in seborrheic keratosis lesions. J Am Acad Dermatol, 79(4): 767-768.
Baumann, LS., Blauvelt, A., Draelos, ZD., Kempers, SE., Lupo, MP., Schlessinger, J., et al. (2018) Safety and efficacy of hydrogen peroxide topical solution, 40%(w/w) in patients with seborrheickeratoses: results from two identical, randomized, double-blind, placebo-controlled, phase 3 studies (A-101-SEBK-301/302). J Am Acad Dermatol, 79(5): 869-877.
Smith, SR., Xu, S., Estes, E., Shanler, SD. (2018) Anatomic Site-Specific Treatment Response With 40% Hydrogen Peroxide (w/w) Topical Formulation for Raised SeborrheicKeratoses: Pooled Analysis of Data from Two Phase 3 Studies. J Drugs Dermatol, 17(10): 1092-1098.
